It is interesting to compare sales reviews from other OTC products in different formats as IMO numbers are increasing. Reality is public don't know new generation is on way for NUH or other sellers and are slow to take up existing offers IMO. Until $ is spent finding target market and advertising to them along with education it will bounce along bottom. Volume can't justify advertising and Hearing companies just sitting back not even promoting older generation devices they can place in sector. This is slow burn as expected.
- Forums
- ASX - By Stock
- NUH
- Review tally
Review tally, page-1121
-
- There are more pages in this discussion • 125 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NUH (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.91M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NUH (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online